The levels of polychlorinated biphenyls (PCBs) in human milk provide an index of exposure of the mother to these compounds and enable the intake by the breast-fed child to be estimated. For valid comparisons between different studies, concentrations should be expressed on a milk fat basis.
In a recently completed UNEP/WHO pilot project on monitoring of organochlorine compounds in human milk in ten countries, great emphasis was placed on analytical quality assurance. To obtain comparable data, a common procedure, that of Sawyer, was adopted for quantitation of PCBs, using Aroclor 1260 as standard. In addition, certain criteria (e.g., age and parity) were established for selection of the mothers to be sampled.
In contrast to the situation with p,p'-DDT and p,p'-DDE, the levels of PCBs in human milk fat were higher in the European countries and Japan than in China, India and Mexico. In fact, PCBs were not detected in human milk in the latter three countries. Although PCBs were detected in some samples in the USA, the median level was below the limit of detection of the method used there (1 mg/kg fat). The median PCB levels reported from Belgium, Israel, Japan and Yugoslavia were 0.81, 0.45, 0.35 and 0.63 mg/kg fat, respectively. Higher median levels were reported from Sweden and the Federal Republic of Germany (0.97 and 2.1 mg/kg fat, respectively). The German samples were not analyzed by the Sawyer method.
Background
Polychlorinated biphenyls (PCBs) are lipophilic and in the human body they are stored mainly in adipose tissue. The levels in blood, hair and urine are relatively low, often below the levels detectable with methodology suitable for use in human monitoring studies. Thus, such studies generally require invasive techniques, using adipose tissue samples collected during surgery or at autopsy. An alternative approach is to use breast milk, which is the major vehicle for excretion of PCBs in lactating women.
In many countries it has been found that, providing the purpose of the study is properly explained, most lactating women are prepared to provide samples of milk for analysis. A large number of studies on the levels of organochlorine compounds (OCCs), including PCBs, in human milk have been carried out since 1950. In some countries, e.g., Japan and Sweden, a large amount of monitoring data is already available and can be compared with newly generated data to detect trends in levels of exposure. It was recognized from the outset that there was a great need for analytical quality assurance (AQA) in the project. Procedures for sample collection and handling and analysis vary among laboratories, but the purpose of the project was not to standardize such methods. It was agreed that each participating laboratory could use methods of its own choice, provided they produced results acceptable according to the criteria established. The quantitation of PCBs in biological samples presents special problems. The usual approach is to base the calculation on some or all the peaks in the gas chromatogram and comparison with a standard. This is often Aroclor 1254 or 1260 or equivalent technical products, which are highly chlorinated PCB mixtures resembling, but not identical with, the PCB profile usually found in human milk. However, the quantitation is only an approximation because there are differences between the profile of the standard and that in human milk. In the UNEP/WHO project a common procedure, that of Sawyer (4), was adopted for quantitation of PCBs, using Aroclor 1260 as standard. However, some laboratories also analyzed the same samples by their usual ("own") method, so that they could compare the results with those found in their earlier studies.
Improvement of the analytical capability of participating laboratories was achieved with the assistance of consultants and by the provision of special training for individual analysts.
The project was divided into two main phases. The first (quality assurance) phase was devoted primarily to training and technical assistance. The second (monitoring) phase was devoted to the actual monitoring of OCCs in human milk, with concurrent AQA. It was agreed that no laboratory should start the analysis ofthe human milk samples until it had achieved satisfactory results in the quality assurance phase.
In the pre-monitoring phase, three batches of interlaboratory AQA samples (one set of solutions of mixtures of OCCs in isooctane and two sets of spiked cows' milk samples) were analyzed. In addition, each laboratory analyzed five replicates of one spiked cows' milk sample to determine the repeatability of its method. The cows' milk samples were spiked at PCB levels previously reported to occur in human milk in countries with PCB contamination problems. In the monitoring phase, one AQA sample (spiked cows' milk) was analyzed with every five to ten human milk samples as an intralaboratory control. The results of these analyses also gave a measure of the reproducibility of the analytical procedure used. In addition, two sets of interlaboratory AQA samples were analyzed during the monitoring phase. The criterion for acceptance of AQA results was that they should lie within + 30% of the spiked level; in most cases they were within ± 20% during the monitoring phase.
In order to improve the comparability of results from the different participating countries, certain criteria were established for selection of the mothers to be sampled, e.g., age and parity. Mothers known to have been occupationally exposed to the OCCs studied were excluded. Samples were collected, mostly during 1981-1982, from at least 50 mothers living in a single geographical area in each country (except for the USA, where samples collected in 22 states in an earlier study were analyzed). Data from the project provide an international comparison of the concentrations of certain OCCs in human milk. However, since only a limited number of mothers in a single geographical area in each country have been analyzed, far reaching conclusions concerning intercountry differences in levels cannot be drawn. The results of the quality assurance studies both before and during the actual monitoring provide a measure of the validity and comparability of the results.
In contrast to the situation with p,p'-DDT (Fig. 1 ) and p,p'-DDE (Fig. 2) , the levels of PCBs in human milk fat were higher in the European countries and Japan than in China, India and Mexico (Fig. 3) . In fact, PCBs were not detected in human milk in the latter three countries. In the case of China and India, this was confirmed by analysis of some of the samples in Japan and Sweden. Although PCBs were detected in some samples in the USA, the median level in milk fat was below the level of detection of the analytical method applied there (1 mg/kg fat). The highest PCB levels were reported by the participating institutions in the Federal Republic of Germany and Sweden (median levels 2.1 and 1.3 mg/kg fat, respectively) ( Tables 1 and  2 ).
The data from Osaka in Japan indicate that the levels of PCBs in human milk fat there have decreased slightly during the period 1977-1981. Similarly, the data from Uppsala in Sweden suggest a slight decrease in levels in breast milk fat there between 1978-1979 and 1981. However, the data from Hanau in the Federal Republic of Germany show no indication of a downward trend in PCB levels there, rather the reverse.
The GC pattern of the PCBs found in typical human milk samples collected in the different countries are shown in Figure 4 . All the chromatograms were run on the 5% OV 101 column specified in the Sawyer procedure for PCB quantitation (4 that were used to quantify the PCB levels. Inspection of the chromatograms in Figure 4 shows that the PCB profiles in the Aroclor 1260 standard and in the human milk from the different countries are fairly similar. This confirms the suitability of using Aroclor 1260 as a standard in this project. The fact that the GC patterns of PCBs in breast milk samples from different countries are similar is somewhat surprising, since the commercial PCB products released into the environment in different countries differ in composition. In general, the most chlorinated PCBs are the most persistent and most abundant in human tissues. The peaks denoted 146, 174 and 280 dominated in the gas chromatograms shown: these peaks represent heavily chlorinated PCBs.
The intakes of PCBs by the breast-fed infant were calculated assuming that the child consumed 130 g milk/ kg body-weight per day and that the milk contains 3.5% (w/w) fat. These assumptions are supported by data from a WHO collaborative study on breast-feeding (5) . The calculated intakes are shown in Table 3 .
Data from Some Other Recent Studies
The results of an extensive study by Noren (6) (7) .
The results of a recent 3-cohort study in the Federal Republic of Germany show mean PCB levels of about 2 mg/kg on a fat basis (8) .
In a longitudinal study on individual mothers, Noren has shown (9) that the level of PCBs in the fat of milk of primiparae is higher than that in that of secundiparae. This agrees with results obtained in the UNEP/WHO project and in earlier studies in Japan. This difference is due to the net loss of PCBs that occurs from the mother during lactation and to the second fetus.
In Japan, Sweden, the USA (Michigan) and several other countries, fish is a major source of dietary PCBs. Studies in Sweden (10), Japan (3) and the USA (11) indicate that the levels of PCBs in human milk fat are higher in women who consume large amounts of fish than among vegetarians and others who consume little or no fish.
Studies by Noren (9) show that there are only small fluctuations (a slow downward trend) in the level of PCBs in the fat of breast milk during the first few months of lactation. We have found similar results in our own laboratory. Thus the time post partum at which the milk samples are collected has little effect on the PCB levels expressed on a fat basis.
Conclusion
In the light of the above data it is obvious that the analysis of human milk for PCBs can provide valuable information on exposure of both the mother and the breast-fed infant to these persistent environmental contaminants. However, care must be exercised when comparing results from different laboratories where different methods of analysis are used and when different criteria have been used in selecting the mothers to be sampled.
It is also imperative that an adequate quality assurance program be included in each study if valid results are to be obtained.
